Should Growth Investors Buy This Revolutionary Small-Cap Stock?
Achieving success as a growth investor revolves around picking companies that are taking new and potentially winning approaches to solving existing problems. These businesses can take their place as disruptors in a particular market, which can fuel growth in revenue and profits.
Minimally invasive medical devices maker (NASDAQ: ANGO) may be such a company. Let's dive into its fundamentals and valuation to find out whether its stock is a buy for growth investors.
Due to its modest $365 million market capitalization, AngioDynamics flies under the radar of most investors. But since its founding in 1988, the company's cutting-edge innovations used to treat cancer and peripheral vascular disease have won favor and recognition among radiologists and surgeons.
Source Fool.com
